Form 8-K - Current report:
SEC Accession No. 0001493152-22-027719
Filing Date
2022-10-05
Accepted
2022-10-05 17:10:49
Documents
15
Period of Report
2022-10-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42092
2 ex99-1.htm EX-99.1 17203
3 ex99-1_001.jpg GRAPHIC 3745
  Complete submission text file 0001493152-22-027719.txt   293532

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bfri-20221005.xsd EX-101.SCH 4078
5 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bfri-20221005_def.xml EX-101.DEF 27210
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bfri-20221005_lab.xml EX-101.LAB 37667
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bfri-20221005_pre.xml EX-101.PRE 25831
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6073
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 221296409
SIC: 2834 Pharmaceutical Preparations